RxDoctor Payments Data

Ramesh Marahatta, MD

Nephrology · Springfield, ORNPI 1679700280

Payments from drug & device makers

What this record shows

This record is dominated by other: $18,883 of the $19,275 with a category attached, or 98.0%. Angiodynamics, Inc. accounts for 98.0% of it on its own, with 8 other manufacturers making up the rest. Among nephrology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,275in general payments, 2019–2025

Across 24 payments — averaging $803.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$19K
  • Genentech USA, Inc.$80
  • Otsuka America Pharmaceutical, Inc.$64
  • AstraZeneca$62
  • Travere Therapeutics, Inc.$60
  • Amgen$46
  • plus $80 from 3 others

What the payments were for

  • Food & beverage$3792%
  • Education$120%
  • Other$18,88398%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,275 in reported general payments places this provider in the 95th percentile of 120 nephrology providers in Oregon.

See all nephrology providers in Oregon

Medicare billing

Part B allowed, 2024
$226,177
Medicare patients
429
Services billed
2,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol149$108,920
JardianceEmpagliflozin44$34,153
LokelmaSodium Zirconium Cyclosilicate23$9,639
Sevelamer Carbonate57$8,642
Calcitriol148$2,290
Lisinopril114$1,702
Losartan Potassium156$1,690
Calcium Acetate19$1,675
Furosemide183$1,543
Amlodipine Besylate121$1,539
Hydralazine Hcl100$1,487
Cinacalcet Hcl14$1,480
Clonidine16$1,396
Potassium Chloride83$1,274
Midodrine Hcl25$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$62$118,558172 claims
ANI Pharmaceuticals, Inc.Valsartan$24$30919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 nephrology providers in Oregon.

Other nephrology in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →